PT3160500T - Composição imunogénica de clostridium difficile - Google Patents

Composição imunogénica de clostridium difficile

Info

Publication number
PT3160500T
PT3160500T PT157334046T PT15733404T PT3160500T PT 3160500 T PT3160500 T PT 3160500T PT 157334046 T PT157334046 T PT 157334046T PT 15733404 T PT15733404 T PT 15733404T PT 3160500 T PT3160500 T PT 3160500T
Authority
PT
Portugal
Prior art keywords
immunogenic composition
clostridium difficile
difficile immunogenic
clostridium
composition
Prior art date
Application number
PT157334046T
Other languages
English (en)
Inventor
Castado Cindy
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1411306.2A external-priority patent/GB201411306D0/en
Priority claimed from GB201411371A external-priority patent/GB201411371D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of PT3160500T publication Critical patent/PT3160500T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT157334046T 2014-06-25 2015-06-25 Composição imunogénica de clostridium difficile PT3160500T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1411306.2A GB201411306D0 (en) 2014-06-25 2014-06-25 Immunogenic composition
GB201411371A GB201411371D0 (en) 2014-06-26 2014-06-26 Immunogenic composition

Publications (1)

Publication Number Publication Date
PT3160500T true PT3160500T (pt) 2019-11-11

Family

ID=53498986

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157334046T PT3160500T (pt) 2014-06-25 2015-06-25 Composição imunogénica de clostridium difficile

Country Status (18)

Country Link
US (1) US20170218031A1 (pt)
EP (2) EP3160500B1 (pt)
JP (2) JP6688233B2 (pt)
CN (1) CN106536544B (pt)
BE (1) BE1022949B1 (pt)
BR (1) BR112016030096B1 (pt)
CA (1) CA2952118A1 (pt)
CY (1) CY1122145T1 (pt)
DK (1) DK3160500T3 (pt)
ES (1) ES2749701T3 (pt)
HR (1) HRP20191864T1 (pt)
HU (1) HUE045936T2 (pt)
LT (1) LT3160500T (pt)
MX (1) MX2016017094A (pt)
PL (1) PL3160500T3 (pt)
PT (1) PT3160500T (pt)
SI (1) SI3160500T1 (pt)
WO (1) WO2015197737A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170238A2 (en) 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
MX2020013623A (es) 2018-06-19 2021-03-25 Glaxosmithkline Biologicals Sa Composicion inmunogenica.
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
AU614755B2 (en) 1987-06-05 1991-09-12 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Autocrine motility factors in cancer diagnosis and management
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0382271B1 (en) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
DK0812593T4 (da) 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
CN1176658A (zh) 1994-10-24 1998-03-18 蛇药制品有限公司 治疗和预防艰难梭菌疾病的疫苗和抗毒素
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0832282A1 (en) 1995-06-02 1998-04-01 Incyte Pharmaceuticals, Inc. IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES
JP2002542169A (ja) * 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
WO2001073030A2 (en) 2000-03-28 2001-10-04 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
AU2003304316A1 (en) * 2002-11-08 2005-01-28 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
SG11201402375VA (en) * 2011-12-08 2014-10-30 Novartis Ag Clostridium difficile toxin-based vaccine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
JP6290918B2 (ja) * 2012-12-05 2018-03-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition

Also Published As

Publication number Publication date
MX2016017094A (es) 2017-05-03
BR112016030096A8 (pt) 2021-07-06
BE1022949B1 (fr) 2016-10-21
DK3160500T3 (da) 2019-11-11
EP3160500B1 (en) 2019-08-21
CN106536544A (zh) 2017-03-22
SI3160500T1 (sl) 2019-11-29
JP6688233B2 (ja) 2020-04-28
BE1022949A1 (fr) 2016-10-21
BR112016030096B1 (pt) 2023-10-03
WO2015197737A1 (en) 2015-12-30
BR112016030096A2 (pt) 2017-08-22
ES2749701T3 (es) 2020-03-23
JP2017520573A (ja) 2017-07-27
CN106536544B (zh) 2020-04-07
EP3636278A3 (en) 2020-07-15
HUE045936T2 (hu) 2020-01-28
JP2020100625A (ja) 2020-07-02
US20170218031A1 (en) 2017-08-03
LT3160500T (lt) 2019-10-25
PL3160500T3 (pl) 2020-02-28
EP3160500A1 (en) 2017-05-03
CY1122145T1 (el) 2020-11-25
EP3636278A2 (en) 2020-04-15
HRP20191864T1 (hr) 2020-01-10
CA2952118A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
ZA201702401B (en) Composition with reduced immunogenicity
IL248223B (en) Compositions of vaccine
GB201501859D0 (en) Composition
IL251479B (en) components
GB201410905D0 (en) Composition
GB201408167D0 (en) Compositions
GB201403017D0 (en) Composition
HK1243341A1 (zh) 起泡減少的疫苗組合物
GB201414910D0 (en) Composition
GB201403561D0 (en) Composition
PL3160500T3 (pl) Immunogenna kompozycja clostridium difficile
GB201420306D0 (en) Compositions
GB201414555D0 (en) Composition
GB201410493D0 (en) Composition
GB201420628D0 (en) Composition
GB201415483D0 (en) Composition
GB201404390D0 (en) Composition
GB201403550D0 (en) Composition
GB201402648D0 (en) Composition
GB201411371D0 (en) Immunogenic composition
GB201411306D0 (en) Immunogenic composition
GB201401883D0 (en) Combination immunogenic compositions
EP3116537A4 (en) Immunogenic compositions
GB201502355D0 (en) Composition
GB201421660D0 (en) Composition